Evidence map›Paper›PMID 22479485›Full record

ArticlePloS one2012

Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection.

Jintanat Ananworanich, Alexandra Schuetz, Claire Vandergeeten, Irini Sereti, Mark de Souza, Rungsun Rerknimitr, Robin Dewar, Mary Marovich, Frits van Griensven, Rafick Sekaly and 14 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02475915 (A Randomized Study to Compare the Efficacy of Vorinostat/Hydroxychloroquine/Maraviroc), which is not on this map. Cited by 211 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
211citing papers in PubMed, 3 pooled it
14.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02475915 phase1 / phase2completednot on this mapstarted 2015, after this paper: background citation

A Randomized Study to Compare the Efficacy of Vorinostat/Hydroxychloroquine/Maraviroc (VHM) in Controlling HIV After Treatment Interruption in Subjects Who Initiated ART During Acute HIV Infection

TypeinterventionalSponsorSEARCH Research FoundationRan2015 to 2016Enrolled15ConditionsAcute HIV InfectionArmsVorinostat, Hydroxychloroquine, Maraviroc, Tenofovir, Emtricitabine
3 · Its place in the literature

Who cites it

211 citing papers in PubMed, 3 syntheses or guidelines pooled it, 310 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Article

151 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 10 institutions in 2 countries.

Jintanat AnanworanichSouth East Asia Research Collaboration with Hawaii, Pathumwan, Bangkok, Thailand. jintanat.a@searchthailand.org
Alexandra Schuetz
Claire Vandergeeten
Irini Sereti
Mark de Souza
Rungsun Rerknimitr
Robin Dewar
Mary Marovich
Frits van Griensven
Rafick Sekaly
Suteeraporn Pinyakorn
Nittaya Phanuphak
Rapee Trichavaroj
Wiriya Rutvisuttinunt
Nitiya Chomchey
Robert Paris
Sheila Peel
Victor Valcour
Frank Maldarelli
Nicolas Chomont
Nelson Michael
Praphan Phanuphak
Jerome H Kim
RV254/SEARCH 010 Study Group
Armed Forces Research Institute of Medical Science · THThai Red Cross Society · THChulalongkorn University · THVaccine & Gene Therapy Institute of Florida · USHIV Netherlands Australia Thailand Research Collaboration · THMinistry of Public Health · THNational Institutes of Health Clinical Center · USScience Applications International Corporation (United States) · USUniversity Memory and Aging Center · USVaccine and Gene Therapy Institute

Funding

Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTON, PETER A · 1991 to 2018
$39.9M
HIV Persistence During Suppressive Antiretroviral TherapyZIABC011466 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MALDARELLI, FRANK · 2012 to 2025
$16.0M
Clinical Interventional Studies of HIV ReservoirsZIABC011464 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MALDARELLI, FRANK · 2012 to 2025
$13.2M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS 5P30 AI028697NIAID NIH HHS P30 AI028697NIMH NIH HHS NH-R21MH089341
6 · The paper itself

Abstract

backgroundLimited knowledge exists on early HIV events that may inform preventive and therapeutic strategies. This study aims to characterize the earliest immunologic and virologic HIV events following infection and investigates the usage of a novel therapeutic strategy. METHODS AND

findingsWe prospectively screened 24,430 subjects in Bangkok and identified 40 AHI individuals. Thirty Thais were enrolled (8 Fiebig I, 5 Fiebig II, 15 Fiebig III, 2 Fiebig IV) of whom 15 completed 24 weeks of megaHAART (tenofovir/emtricitabine/efavirenz/raltegravir/maraviroc). Sigmoid biopsies were completed in 24/30 at baseline and 13/15 at week 24. At baseline, the median age was 29 years and 83% were MSM. Most were symptomatic (87%), and were infected with R5-tropic (77%) CRF01_AE (70%). Median CD4 was 406 cells/mm(3). HIV RNA was 5.5 log(10) copies/ml. Median total blood HIV DNA was higher in Fiebig III (550 copy/10(6) PBMC) vs. Fiebig I (8 copy/10(6) PBMC) (p = 0.01) while the median %CD4+CCR5+ gut T cells was lower in Fiebig III (19%) vs. Fiebig I (59%) (p = 0.0008). After 24 weeks of megaHAART, HIV RNA levels of <50 copies were achieved in 14/15 in blood and 13/13 in gut. Total blood HIV DNA at week 0 predicted reservoir size at week 24 (p<0.001). Total HIV DNA declined significantly and was undetectable in 3 of 15 in blood and 3 of 7 in gut. Frequency of CD4+CCR5+ gut T cells increased from 41% at baseline to 64% at week 24 (p>0.050); subjects with less than 40% at baseline had a significant increase in CD4+CCR5+ T cells from baseline to week 24 (14% vs. 71%, p = 0.02).

conclusionsGut T cell depletion and HIV reservoir seeding increases with progression of AHI. MegaHAART was associated with immune restoration and reduced reservoir size. Our findings could inform research on strategies to achieve HIV drug-free remission.

Indexed as

AdultAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCD4-Positive T-LymphocytesCytokinesFemaleHIV-1HIV InfectionsHumansIntestinesLeukocytes, MononuclearMaleReceptors, CCR5T-LymphocytesTreatment OutcomeViral LoadCytokinesReceptors, CCR5

Identifiers

PMID22479485
PMCPMC3316511
OpenAlexW2021905358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.